Call

MODUS Study

On This Page:

Multi-Organ Denervation to Reduce Sympathetic Drive, A Single Blinded, Multi-Center, Prospective Feasibility Study.

About the study

The MODUS Study is a randomized feasibility study evaluating the safety and performance of hepatic (liver) denervation, renal (kidney) denervation or multi-organ (liver and kidney) denervation with Metavention’s iRF Denervation System for the treatment of type 2 diabetes and high blood pressure.

Who can participate

Participants will receive one of these denervation treatments but will not know which one. This study is currently enrolling patients in Australia.

You may be eligible to participate if:

  • Aged between 22 and 70 years old
  • Type 2 diabetes diagnosis:

HbA1c between 48 mmol/mol (6.5%) and 69 mmol/mol(8.5%) AND on a consistent drug regimen up to 2 diabetes medications for at least 90 days

  • Diagnosis of high blood pressure AND on a consistent regimen of up to 2 antihypertensive medications for at least 90 days
  • Waist circumference Caucasians ≥ 102 cm (male) and ≥ 88 cm (female) or

Asians: ≥ 90 cm (male) and ≥ 80 cm (female)

For further information and to see if you are eligible please follow the below link: http://www.modusstudy-au.com/
 
This research project has been approved by The Alfred Human Research Ethics Committee: (HREC/60968/Alfred-2020).
 

Skip to content